KALV - CIK 0001348911
The table below shows KalVista Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$152.91M | -$89.23M | -$75.26M | -$78.13M | -$30.17M | -$44.82M |
| Capital expenditure | $434.00K | $42.00K | $1.20M | $931.00K | $82.00K | $220.00K |
| Investing cash flow | $91.02M | -$84.72M | $41.41M | $57.86M | -$147.65M | $16.75M |
| Dividends paid | - | - | - | - | - |
KalVista Pharmaceuticals, Inc. reported operating cash flow of -$152.91M for fiscal year 2025. That is down 71.4% from -$89.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$13.16M (FY 2016) to -$152.91M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $159.73M | $150.71M | $58.12M | $1.58M | $212.12M | $11.58M |